Dallas’ MedCognetics Gets FDA Clearance for Its AI-Enabled Breast Cancer Screening Software » Dallas Innovates

Can artificial intelligence help detect breast cancers early on, improving outcomes for a diverse group of patients? That’s the goal of an advanced AI software platform from Dallas-based MedCognetics—and last week it received a key clearance from the US Food and Drug Administration.

The software platform, branded as QmTRIAGE, integrates into radiology workflow and has a high rate of detection accuracy, according to Debasish Nag, CEO of MedCognetics. The early-stage startup, which was founded in 2019, aims to: develop the next generation of AI medical imaging technology to find cancer tumors smaller than 2 centimeters in size.

The platform’s “unbiased” advanced imaging algorithm leverages AI and machine learning “to detect the earliest manifestations of cancer in all ethnicities” the company says.

“The American Cancer Society has stated that in 2022, approximately 287,850 new cases of invasive breast cancer will be diagnosed in women,” Nag said in a statement. “The FDA’s [510(k)] clearance is a very important first step for us as we work towards expanding to other realms of cancer.”

Aiming to address a global shortage of radiologists—while reducing ‘burnout’

Debasish Nag:

The QmTRIAGE also aims to help radiologists struggling with unmanageable caseloads, the company said. According to Margaretta Colangelo, an independent analyst focused on AI, there is currently a “10 times” global demand for radiology services compared to the number of available radiologists—and 50% of practicing radiologists are experiencing depression or burnout.

MedCognetics’ AI tech aims to help those overburdened radiologists by providing both the “scale and performance” to address the gap—while improving the efficiency and effectiveness of medical imaging. “Our software’s high detection accuracy enables reduced time for review by radiologists, another key component to improved outcomes,” Nag noted.

Worked with UT Dallas and UT Southwestern on improving outcomes for ‘all ethnicities’

Lakshman Tamil:

Nag says his company placed a great deal of focus on improving outcomes for a diverse society. T:oday’s AI Systems are trained on small, non-diverse data sets, and do not represent all patient races and ethnicities, his company notes.

“MedCognetics is committed to leveraging our technology to help improve outcomes across a diverse group of patients and to do so, partnered with both University of Texas at Dallas and University of Texas Southwestern Medical Center to address these disparities.” Nag said.

Lakshman Tamil, Ph.D., a professor at UT Dallas, is co-founder of MedCognetics.

The company’s core team also includes Chief Medical Officer Vasant Garg, MD; Tim Cogan, Ph.D., head of AI/ML; Quality Manager John Jenkins; Clinical Development Officer Paula Gupta, MD; and Chris Beaty, VP of operations.

Received $750K from the NIH for unbiased AI study

The company—which received $750,000 from the National Institutes for Health for its unbiased AI study—says it leverages “nine independent data sources worldwide” to help it ensure data diversity.

UT Southwestern’s Basak Dogan, MD, is working with the company to help train its system.

“At UTSW we work to integrate existing and pipeline AI algorithms at the earliest stages of disease, which is key to saving lives,” Dogan said in a statement. “We work with MedCognetics to help train their system on detecting early stage breast cancers which is important to help use AI for breast cancer detection as a standalone tool. We’re pleased to partner with MedCognetics in our mission to help maximize lives saved from breast cancer.”

MedCognetics added that its initial patent is pending for the software platform, and two additional related patents are in progress.

Growing use of AI in breast imaging—and concern about racial disparities

The use of AI in breast imaging has been growing rapidly, and currently represents 15% of the total AI imaging market, according to MedCognetics.

The challenge: Studies have shown that the use of artificial intelligence can lead to “data bias” affecting people of color. An investigation by STAT—a health and medicine-oriented news service produced by Boston Globe Media—explored whether AI tools for breast cancer worsen disparities. STAT said “patchy public data in FDA filings” have fueled concern. The investigation noted that when the FDA grants clearances to AI products without requiring them to publicly disclose how extensively their tools have been tested on people of color, it “threatens to worsen already gaping disparities in outcomes within breast cancer, a disease which is 46% more likely to be fatal for Black women.”

MedCognetics’ partnership with UT Dallas and UT Southwestern to address the issue reflects how important the company believes the issue to be. So much so that the company reproduces the above STAT quotation on its own website.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

READ NEXT:

  • Reminder Calendar:

    North Texas has plenty to see, hear, and watch. Here are our editors’ picks. Plus, you’ll find our selections to “save the date.”

  • Peruse Dallas Innovates’ special once-a-year magazines. Each edition is a keeper.

  • Dr. Ahn is working on something very small that may have a profound, life-saving impact on something hugely dangerous. In collaboration with UTSW Medical Center professor Dr. Ganesh Raj and UTHSC San Antonio’s Ratna Vadlamudi, Ahn has created a molecule that can kill an array of cancers, including an aggressive form of breast cancer. The goal of the molecules is to prevent molecular “handshakes” between proteins that can cause out-of-control cell growth that spreads cancer further.

  • UT Dallas marketing professor emeritus Brian Ratchford and his team explored the effects of social media on crowdfunding across nearly 440 GoFundMe campaigns. They found that social media is most helpful in the first 10 days of a campaign. “If a campaign doesn’t do well at the outset, it is unlikely to succeed,” Ratchford said.

  • With a five-year, $11.3 million grant from the National Institute of Neurological Disorders and Stroke, researchers at UT Dallas’ new Human Nociceptor and Spinal Cord Molecular Signature Center are digging into the causes of chronic pain and new ways to treat it. The center’s leader, Dr. Ted Price, says the data generated “will fundamentally change the way that we think about pain and how we develop therapeutics.”